Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
10 resultat
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Arginase-1 (ARG1) is an enzyme that converts the amino acid arginine into urea and ornithine. ARG1 is mainly expressed in hepatocytes but different myeloid cells are also capable of ARG1-expression.
An ARG1-induced arginine depletion suppresses T cell function through the impairment of the T cell
An Intermediate Expanded Use Trial of DFMO
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Study on the Optimal Strategy for Acute-on-chronic Liver Failure With Integrative Treatment
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Study design This prospective, multi-center, parallel, centrally randomized controlled trial was designed in accordance with the Consolidated Standards of Reporting Trials (CONSORT) and Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines, which is led by the
Efficacy Study of Pegylated Recombinant Human Arginase 1 as a Second-line Therapy in Patients With Advanced Liver Cancer
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
This is a phase II, single-arm clinical trial. Approximately 35 subjects will be enrolled in the study. All subjects will be treated with PEG-BCT-100 2.7 mg/kg weekly (day1, 8 and 15). Three week treatment of PEG-BCT-100 is considered as 1 cycle. All subjects will receive PEG-BCT-100 till
Curcumin in Treating Patients With Familial Adenomatous Polyposis
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Specific Aims:
I. To determine in a randomized, double-blinded, placebo-controlled study the tolerability and effectiveness of curcumin to regress intestinal adenomas by measuring duodenal and colorectal/ileal polyp number, and polyp size in familial adenomatous polyposis patients with intact
Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
OBJECTIVES:
Primary
- To determine if combination therapy with topical eflornithine hydrochloride ointment and topical diclofenac sodium gel over 3-months increases the efficacy versus either agent used alone in the treatment of moderately sun-damaged skin.
Secondary
- To evaluate the safety of
Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Selenium for Prevention of Adenomatous Colorectal Polyps
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
OBJECTIVES:
Primary
- Compare the effects of selenium vs placebo on the recurrence of adenomatous colorectal polyps, in terms of histologic type, degree of dysplasia, number, size, and location, in patients with adenomatous colorectal polyps.
- Compare the type, incidence, and outcome of side
Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
PRIMARY OBJECTIVES:
I. To determine the relative efficacy of celecoxib plus eflornithine (DFMO) versus celecoxib plus DFMO placebo in participants with familial adenomatous polyposis (FAP), as evidenced by the percent change from baseline in the number of polyps in focal area(s) of the colorectum in
Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
OBJECTIVES: I. Compare the rate of new skin cancer in patients with previously treated stage 0, I, or II basal or squamous cell skin cancer treated with eflornithine (DFMO) vs placebo. II. Determine whether inhibition of TPA-induced ornithine decarboxylase activity serves as an intermediary marker
Den mest kompletta databasen med medicinska örter som stöds av vetenskapen
- Fungerar på 55 språk
- Växtbaserade botemedel som stöds av vetenskap
- Örter igenkänning av bild
- Interaktiv GPS-karta - märka örter på plats (kommer snart)
- Läs vetenskapliga publikationer relaterade till din sökning
- Sök efter medicinska örter efter deras effekter
- Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent
Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning
